Loading clinical trials...
Loading clinical trials...
This 4 arm study will assess the optimal starting dose of Mircera in the treatment of anemia in patients with non-small cell lung cancer receiving first line myelosuppressive chemotherapy. Patients wi...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Hoffmann-La Roche
NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more
NCT07039422 · Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia
NCT06976918 · Primary Myelofibrosis, Secondary Myelofibrosis, and more
NCT05012111 · Severe Aplastic Anemia, Telomere Biology Disorders, and more
NCT03520647 · Severe Aplastic Anemia (SAA), Hypo-Plastic Myelodysplastic Syndrome (MDS), and more
East Bentleigh
Kurralta Park
Milton
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions